DE69427815T2 - Osteogenese-promoter und mittel gegen osteoporose - Google Patents

Osteogenese-promoter und mittel gegen osteoporose

Info

Publication number
DE69427815T2
DE69427815T2 DE69427815T DE69427815T DE69427815T2 DE 69427815 T2 DE69427815 T2 DE 69427815T2 DE 69427815 T DE69427815 T DE 69427815T DE 69427815 T DE69427815 T DE 69427815T DE 69427815 T2 DE69427815 T2 DE 69427815T2
Authority
DE
Germany
Prior art keywords
osteogenesis
osteogenesis promoter
osteoporose
treating
agent against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427815T
Other languages
English (en)
Other versions
DE69427815D1 (de
Inventor
Yasuo Suzuki
Yutaka Mizushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTT Bio Pharma Co Ltd
Original Assignee
LTT Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTT Institute Co Ltd filed Critical LTT Institute Co Ltd
Application granted granted Critical
Publication of DE69427815D1 publication Critical patent/DE69427815D1/de
Publication of DE69427815T2 publication Critical patent/DE69427815T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69427815T 1993-05-18 1994-05-18 Osteogenese-promoter und mittel gegen osteoporose Expired - Fee Related DE69427815T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14969393 1993-05-18
PCT/JP1994/000798 WO1994026768A1 (en) 1993-05-18 1994-05-18 Osteogenesis promoter and osteoporosis remedy

Publications (2)

Publication Number Publication Date
DE69427815D1 DE69427815D1 (de) 2001-08-30
DE69427815T2 true DE69427815T2 (de) 2001-11-08

Family

ID=15480752

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427815T Expired - Fee Related DE69427815T2 (de) 1993-05-18 1994-05-18 Osteogenese-promoter und mittel gegen osteoporose

Country Status (11)

Country Link
US (1) US5565444A (de)
EP (1) EP0698612B1 (de)
JP (1) JP3197562B2 (de)
AT (1) ATE203544T1 (de)
AU (1) AU6657894A (de)
CA (1) CA2162604C (de)
DE (1) DE69427815T2 (de)
ES (1) ES2163439T3 (de)
GR (1) GR3036736T3 (de)
PT (1) PT698612E (de)
WO (1) WO1994026768A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6579936B1 (en) 1998-07-30 2003-06-17 Dainippon Ink And Chemicals, Inc. Composition of polyarylenesulfide, epoxy resin and oxazoline polymer
EP1119251A4 (de) * 1998-10-07 2004-03-24 Univ Arkansas Verfahren für das screening auf wirkstoffe für die anabole knochentherapie, die die apoptosis kontrollieren, und ihre verwendung
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
CA2462456C (en) 2001-10-03 2010-05-04 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
US3741990A (en) * 1969-07-28 1973-06-26 Upjohn Co Organic compounds and processes
EP0496520A1 (de) * 1991-01-22 1992-07-29 Merck & Co. Inc. Knochenaktive Verbindungen
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents

Also Published As

Publication number Publication date
ATE203544T1 (de) 2001-08-15
EP0698612A4 (de) 1998-05-27
CA2162604A1 (en) 1994-11-24
EP0698612A1 (de) 1996-02-28
AU6657894A (en) 1994-12-12
GR3036736T3 (en) 2001-12-31
JP3197562B2 (ja) 2001-08-13
PT698612E (pt) 2001-11-30
ES2163439T3 (es) 2002-02-01
WO1994026768A1 (en) 1994-11-24
CA2162604C (en) 2002-09-17
EP0698612B1 (de) 2001-07-25
US5565444A (en) 1996-10-15
DE69427815D1 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
DK0712276T3 (da) Sanitære sammensætninger
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
CA2234469A1 (en) Use of an encapsulated bioactive composition
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
NO20006221L (no) Fremgangsmåte for bekjempelse av skadedyr
NO20065784L (no) Steroidforbindelser og anvendelse av slike
ES2167463T3 (es) Componentes de un compuesto medicinal que comprenden derivados n-sustituidos de la o-toluidina y preparacion percutaneamente absorbible.
DE69427815T2 (de) Osteogenese-promoter und mittel gegen osteoporose
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
ZA899670B (en) Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DE69418744T2 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
KR930012036A (ko) 골 흡수 억제용 약제학적 조성물
DE69115745D1 (de) Verwendung von Steroidderivaten zur Behandlung der Endometriose
ATE274904T1 (de) 4,5-dihydroxy-2-cyclopenten-1-on für die behandlung von diabetes mellitus
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
ES2099658B1 (es) Nuevos derivados de benc(e)indeno, procedimiento de prepararlos, composicion farmaceutica que los contiene, procedimiento de prepararla y utilizacion de aquellos.
TH20329A (th) สิ่งป้องกันโรคและสิ่งหรือยาใช้รักษาโรคสำหรับบาดแผล และ/หรือการอักเสบซึ่งเกี่ยวกับตา
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LTT BIO-PHARMA CO., LTD., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee